Blood vessel cells are clustering around immune aggregates in Crohn's patients - and triggering the scarring that leads to surgery

Ten to twenty percent of Crohn's Disease patients develop fibrostenosis - a complication where scar tissue accumulates in the gut wall, narrowing the intestinal lumen until obstruction becomes inevitable. When it gets bad enough, surgery is the only option. There is no drug that treats it. No pharmaceutical company has a late-stage pipeline candidate for it. The scarring process has been poorly understood at the cellular level, which makes it hard to develop therapies against something you can't clearly see.

A new study from the Earlham Institute, the University of Edinburgh, and Heriot-Watt University has pulled back that curtain, using single-cell RNA sequencing to map exactly which cells drive fibrosis and how they coordinate the damage.

The submucosa as ground zero

The researchers analyzed gut tissue samples from Crohn's patients and discovered that the most extensive scar tissue buildup occurs in the submucosa - a connective tissue layer beneath the gut's inner lining. This is significant because it suggests the submucosa may be where fibrosis initiates, rather than simply being one of several affected layers.

Within the submucosa, inflammation brings clusters of immune cells called Crohn's lymphoid aggregates (CLAs). These aggregates are a hallmark of the disease. But the new finding is what's happening around them.

Endothelial cells where they shouldn't be

Using single-cell RNA sequencing (scRNA-seq), the researchers found an unusual accumulation of endothelial cells - cells that normally line blood vessels - clustering around the CLAs. These endothelial cells aren't forming normal blood vessels. Instead, they appear to be signaling to fibroblasts and myofibroblasts (the cells that build scar tissue) either directly or through macrophages as intermediaries.

The message those signals carry: start producing collagen. Lots of it.

The result is excessive collagen deposition - scar tissue - that progressively narrows the gut lumen. As the space inside the intestine shrinks, patients develop the obstruction symptoms that eventually make surgery necessary.

This signaling chain - from endothelial cell clusters around immune aggregates, through macrophages, to collagen-producing fibroblasts - represents a potential therapeutic target. If the signaling can be interrupted, it might be possible to slow or prevent the fibrosis that current medications cannot touch.

Combining pathology with genomics

The study's approach combined traditional histological (tissue-level) analysis with single-cell transcriptomics, allowing the team to link what they could see under a microscope with what was happening at the molecular level within individual cells. Professor Irene Papatheodorou, head of data science at the Earlham Institute, noted that this integration reveals cellular interactions that aren't discernible through either method alone.

Professor Mark Arends at the University of Edinburgh described the effort as six years of collaboration between pathologists, gastroenterologists, biomedical scientists, and computational experts across four institutions - including the Sanger Institute - working to identify new therapeutic targets.

The work is part of a broader international effort to create a gut cell atlas, a comprehensive research tool that catalogs and characterizes the cells of the digestive system to accelerate understanding of gastrointestinal diseases.

Next steps and honest limitations

The researchers are direct about what they haven't yet proven. The interactions they've mapped need further confirmation, and the next phase of research will involve analyzing more gut samples using the same methodology to validate the patterns observed so far.

The study sample size - while sufficient for the single-cell approach - represents a limited number of patients. Whether the endothelial cell clustering and signaling patterns hold consistently across the full diversity of Crohn's disease presentations remains to be determined.

Single-cell sequencing captures a snapshot of gene expression at one moment, not a movie of how the process unfolds over time. The researchers can see that endothelial cells, macrophages, and fibroblasts are in the same neighborhood and expressing the right signals, but proving the causal chain will require additional experimental work.

Still, for a complication that affects up to one in five Crohn's patients and has zero drug treatments, having a cellular mechanism to target is a meaningful advance. Funded by The Leona M. and Harry B. Helmsley Charitable Trust, the largest private philanthropy focused on Crohn's Disease, this work lays groundwork for therapeutic development that could spare patients from the surgical interventions that are currently their only recourse.